Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift = 99%,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EPAS1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
HIF-2-alpha also known as hypoxia-inducible factor 2-alpha or EPAS1 plays a significant role in cellular response to oxygen levels. Mechanically HIF-2-alpha functions as a transcription factor that activates certain genes when oxygen is low. The protein typically weighs around 118 kDa. It is expressed in various tissues but particularly in endothelial cells and some neuronal tissues. These sites highlight its importance in organs requiring tight regulation of oxygen.
Biological function summary
HIF-2-alpha regulates the expression of genes involved in energy metabolism and angiogenesis. The protein forms a complex by dimerizing with the HIF-1-beta subunit which is necessary for transcriptional activity. Through this complex formation and activity it influences processes such as erythropoiesis and regulates factors like vascular endothelial growth factor (VEGF). Therefore HIF-2-alpha contributes to the adaptation of cells and tissues under hypoxic conditions.
Pathways
HIF-2-alpha engages in the hypoxia signaling pathway playing an essential part by modulating gene expression in response to low oxygen availability. This role impacts other proteins such as HIF-1-alpha sharing overlapping functions but with distinct target genes. Additionally HIF-2-alpha is involved in the mTOR pathway which influences cell growth and metabolism through its interaction with the nutrient-sensing regulatory pathway.
Researchers have linked HIF-2-alpha with conditions like renal cell carcinoma and pulmonary hypertension. The protein's dysregulation can lead to altered expression of angiogenic factors promoting tumor growth and survival. In particular its connection with VEGF exemplifies its role in these pathologies by facilitating aberrant blood vessel formation. Such interactions further highlight the potential of HIF-2-alpha as a therapeutic target in disease modulation.
